Kiora Pharmaceuticals Announces Exclusive KIO-301 License with CKD

What Happened
Kiora Pharmaceuticals, Inc. announced an Exclusive License and Development Agreement with Chong Jun Dang Pharmaceutical Corporation (CKD), effective August 20, 2026. Under the agreement Kiora granted CKD an exclusive, sublicensable license to develop, manufacture, commercialize and seek regulatory approval for KIO-301 in South Korea for use in retinitis pigmentosa and other ophthalmology indications. Kiora issued a press release on August 19, 2026, disclosing the signing.

Key Details

• Agreement effective date: August 20, 2026. Press release dated August 19, 2026.
• Up-front payment to Kiora: $1.0 million.
• Kiora is eligible for additional clinical, regulatory and sales milestone payments and for double-digit royalties on net sales in the Territory (South Korea).
• CKD will lead development and commercialization in South Korea; Kiora expects CKD, Laboratoires Théa and Senju Pharmaceutical to coordinate a single global Phase 3 trial for KIO-301.
• Certain confidential portions of the agreement were omitted from the public exhibit.

Why It Matters
This deal provides Kiora with immediate non-dilutive cash ($1.0M) and the potential for milestone and royalty revenues if KIO-301 advances and is commercialized in South Korea. Having a local commercialization partner (CKD) shifts regional development and regulatory work to CKD, which can accelerate market entry in that territory and reduce Kiora’s direct commercialization burden. Coordination with existing partners on a single global Phase 3 could streamline clinical development. Investors should note the agreement is limited to South Korea and some contract terms were redacted in the public filing.